291 related articles for article (PubMed ID: 27426929)
1. A double blind, randomized, placebo controlled trial of the efficacy, quality of life and safety of food allergen-specific sublingual immunotherapy in client owned dogs with adverse food reactions: a small pilot study.
Maina E; Cox E
Vet Dermatol; 2016 Oct; 27(5):361-e91. PubMed ID: 27426929
[TBL] [Abstract][Full Text] [Related]
2. Changes in cytokine profiles following treatment with food allergen-specific sublingual immunotherapy in dogs with adverse food reactions.
Maina E; Devriendt B; Cox E
Vet Dermatol; 2017 Dec; 28(6):612-e149. PubMed ID: 28736961
[TBL] [Abstract][Full Text] [Related]
3. A comparative study of subcutaneous, intralymphatic and sublingual immunotherapy for the long-term control of dogs with nonseasonal atopic dermatitis.
Fischer NM; Rostaher A; Favrot C
Vet Dermatol; 2020 Oct; 31(5):365-e96. PubMed ID: 32537789
[TBL] [Abstract][Full Text] [Related]
4. Use of immunostimulatory liposome-nucleic acid complexes in allergen-specific immunotherapy of dogs with refractory atopic dermatitis - a pilot study.
Mueller RS; Veir J; Fieseler KV; Dow SW
Vet Dermatol; 2005 Feb; 16(1):61-8. PubMed ID: 15725107
[TBL] [Abstract][Full Text] [Related]
5. Food allergen-specific sublingual immunotherapy modulates peripheral T cell responses of dogs with adverse food reactions.
Maina E; Devriendt B; Cox E
Vet Immunol Immunopathol; 2019 Jun; 212():38-42. PubMed ID: 31213250
[TBL] [Abstract][Full Text] [Related]
6. Food-specific sublingual immunotherapy is well tolerated and safe in healthy dogs: a blind, randomized, placebo-controlled study.
Maina E; Pelst M; Hesta M; Cox E
BMC Vet Res; 2017 Jan; 13(1):25. PubMed ID: 28100257
[TBL] [Abstract][Full Text] [Related]
7. Rush sublingual immunotherapy in canine atopic dermatitis: a prospective pilot study.
Fujimura M; Ishimaru H
Pol J Vet Sci; 2016; 19(1):3-6. PubMed ID: 27096781
[TBL] [Abstract][Full Text] [Related]
8. Long-term effects of intralymphatic immunotherapy (ILIT) on canine atopic dermatitis.
Timm K; Mueller RS; Nett-Mettler CS
Vet Dermatol; 2018 Apr; 29(2):123-e49. PubMed ID: 29327474
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of short-term combination of intralymphatic allergen immunotherapy and lokivetmab treatment in canine atopic dermatitis: A double-blinded, controlled, randomised study.
van Amersfort K; Vernooij JCM; van der Lee A
Vet Dermatol; 2023 Oct; 34(5):373-384. PubMed ID: 37186491
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of a House Dust Mite Sublingual Allergen Immunotherapy Tablet in Adults With Allergic Asthma: A Randomized Clinical Trial.
Virchow JC; Backer V; Kuna P; Prieto L; Nolte H; Villesen HH; Ljørring C; Riis B; de Blay F
JAMA; 2016 Apr; 315(16):1715-25. PubMed ID: 27115376
[TBL] [Abstract][Full Text] [Related]
11. An evidence-based analysis of house dust mite allergen immunotherapy: a call for more rigorous clinical studies.
Calderon MA; Casale TB; Nelson HS; Demoly P
J Allergy Clin Immunol; 2013 Dec; 132(6):1322-36. PubMed ID: 24139829
[TBL] [Abstract][Full Text] [Related]
12. Results of allergen-specific immunotherapy in atopic dogs with Malassezia hypersensitivity: a retrospective study of 16 cases.
Åberg L; Varjonen K; Åhman S
Vet Dermatol; 2017 Dec; 28(6):633-e157. PubMed ID: 28748560
[TBL] [Abstract][Full Text] [Related]
13. Assessment of sublingual immunotherapy efficacy in children with house dust mite-induced allergic asthma optimally controlled by pharmacologic treatment and mite-avoidance measures.
Pham-Thi N; Scheinmann P; Fadel R; Combebias A; Andre C
Pediatr Allergy Immunol; 2007 Feb; 18(1):47-57. PubMed ID: 17295799
[TBL] [Abstract][Full Text] [Related]
14. A blinded, randomized, placebo-controlled, dose determination trial of lokivetmab (ZTS-00103289), a caninized, anti-canine IL-31 monoclonal antibody in client owned dogs with atopic dermatitis.
Michels GM; Ramsey DS; Walsh KF; Martinon OM; Mahabir SP; Hoevers JD; Walters RR; Dunham SA
Vet Dermatol; 2016 Dec; 27(6):478-e129. PubMed ID: 27647569
[TBL] [Abstract][Full Text] [Related]
15. Clinical efficacy of sublingual allergen-specific immunotherapy in 22 cats with atopic dermatitis.
Foj R; Carrasco I; Clemente F; Scarampella F; Calvet A; Prats A; Vivancos S; Brazís P; Puigdemont A
Vet Dermatol; 2021 Feb; 32(1):67-e12. PubMed ID: 33399258
[TBL] [Abstract][Full Text] [Related]
16. A blinded, randomized clinical trial comparing the efficacy and safety of oclacitinib and ciclosporin for the control of atopic dermatitis in client-owned dogs.
Little PR; King VL; Davis KR; Cosgrove SB; Stegemann MR
Vet Dermatol; 2015 Feb; 26(1):23-30, e7-8. PubMed ID: 25496303
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of sublingual immunotherapy for allergic asthma: retrospective meta-analysis of randomized, double-blind and placebo-controlled trials.
Tao L; Shi B; Shi G; Wan H
Clin Respir J; 2014 Apr; 8(2):192-205. PubMed ID: 24118881
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of low dose immunotherapy in the treatment of canine atopic dermatitis: a prospective, double-blinded, clinical study.
Colombo S; Hill PB; Shaw DJ; Thoday KL
Vet Dermatol; 2005 Jun; 16(3):162-70. PubMed ID: 15960629
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy (oral and sublingual) for food allergy to fruits.
Yepes-Nuñez JJ; Zhang Y; Roqué i Figuls M; Bartra Tomas J; Reyes JM; Pineda de la Losa F; Enrique E
Cochrane Database Syst Rev; 2015 Nov; 2015(11):CD010522. PubMed ID: 26558953
[TBL] [Abstract][Full Text] [Related]
20. Sublingual immunotherapy in children with allergic rhinoconjunctivitis mono-sensitized to house-dust-mites: a double-blind-placebo-controlled randomised trial.
Aydogan M; Eifan AO; Keles S; Akkoc T; Nursoy MA; Bahceciler NN; Barlan IB
Respir Med; 2013 Sep; 107(9):1322-9. PubMed ID: 23886432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
